RxDoctor Payments Data

Hasan Dani, MD

Urology · Caldwell, IDNPI 1902337066

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,677 of the $4,128 with a category attached, or 64.8%. 26 manufacturers reported payments, led by EDAP Technomed Inc at 41.1% of the total. Reporting peaked in 2024 at $2,797 and has fallen 66.6% since, to $935 in 2025.

$4,128in general payments, 2019–2025

Across 107 payments — averaging $38.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EDAP Technomed Inc$2K
  • Johnson & Johnson$443
  • AbbVie$284
  • Merck$207
  • Astellas Pharma US Inc$207
  • Accord Healthcare, Inc.$159
  • plus $1K from 20 others

What the payments were for

  • Travel & lodging$1,43335%
  • Food & beverage$2,67765%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,128 in reported general payments places this provider in the 65th percentile of 55 urology providers in Idaho.

See all urology providers in Idaho

Medicare billing

Part B allowed, 2024
$255,324
Medicare patients
308
Services billed
9,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron36$29,952
Abiraterone Acetate15$12,133
Tamsulosin Hcl162$1,887
Finasteride79$851
Oxybutynin Chloride ErOxybutynin Chloride34$381
Ciprofloxacin Hcl31$170
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$104
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim32$101
Ondansetron Hcl18$94
Prednisone15$94
Oxycodone Hcl32$92
Cephalexin26$70
Diazepam36$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$207$29,95236 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$28$12,13315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 55 urology providers in Idaho.

Other urology in Caldwell

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →